Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

Article

The focus of this clinical trial is to assess how well tadalafil works in treating patients who are undergoing surgery for cancer of the oral cavity or oropharynx.

Study Type: Interventional

Age/Sex Requirement: 18 years+ (None)

Sponsor: University of Miami Sylvester Comprehensive Cancer Center

Clinicaltrials.gov Identifier: NCT00843635

Purpose: To assess how well tadalafil works in treating patients who are undergoing surgery for cancer of the oral cavity or oropharynx. The primary outcome measure is immune response as assessed by the number of CD4+ and CD8+ cells in tumor tissue by immunohistochemistry and proliferation of CD8+ lymphocytes in peripheral blood mononuclear cells by fluorescence activated cell sorting. Secondary outcomes measures include optimal dosing schedule for tadalafil, treatment-related side effects, progression-free survival, and overall survival.

Click here to access additional information from this third-party website.

Related Videos
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
A panel of 4 experts on asthma
A panel of 4 experts on asthma
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.